Sarepta Therapeutics Inc (SRPT), VIVUS, Inc. (VVUS): The Week’s Biotech Winner and Loser

Page 2 of 2

VIVUS, Inc. (NASDAQ:VVUS) is entering an erectile dysfunction field that’s stiffening with competition from generics. The Stendra news at least reminds people the drug still exists — and Stendra’s potential launch could steer some attention away from Qsymia’s soft launch.

Brandy Betz has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

The article The Week’s Biotech Winner and Loser originally appeared on Fool.com and is written by Brandy Betz.

Brandy is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2